However, recent clinical trials have indicated that a larger number of patients with breast cancer may be sensitive to PARP inhibitors because of other DNA-repair gene mutations, DNA-repair deficiency, and somatic BRCA1 and BRCA2 mutations. This evidence concerns the gene BRCA2 and breast carcinoma.